Shareholder Alert: The Ademi Firm investigates whether Avidity Biosciences Inc. is obtaining a Fair Price for its Public Shareholders

Group 1 - Avidity is under investigation by the Ademi Firm for potential breaches of fiduciary duty and other legal violations related to its transaction with Novartis [1][3] - In the transaction, Avidity shareholders are set to receive $72.00 per share, which values the company at approximately $12 billion on a fully diluted basis [2] - The transaction agreement imposes significant penalties on Avidity for accepting competing bids, raising concerns about the board's fulfillment of fiduciary duties to shareholders [3]